Wed, Sep 17, 2014, 7:13 AM EDT - U.S. Markets open in 2 hrs 17 mins


% | $
Quotes you view appear here for quick access.

Novartis AG Message Board

supermichaelcarbajal 2 posts  |  Last Activity: Feb 28, 2013 1:22 AM Member since: Jan 25, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • supermichaelcarbajal by supermichaelcarbajal Feb 28, 2013 1:22 AM Flag

    Roth Capital upped their price target on shares of TriMas Corp (NYSE: TRS) to $33.00 in a research note issued on Wednesday. The firm currently has a “buy” rating on the stock.
    TRS has been the subject of a number of other recent research reports. Analysts at Jefferies Group reiterated a “hold” rating on shares of TriMas Corp in a research note to investors on Wednesday. They now have a $33.00 price target on the stock, up previously from $29.00.
    Four research analysts have rated the stock with a buy rating, and one has assigned a hold rating to the company’s stock. TriMas Corp presently has a consensus rating of “buy” and an average target price of $32.00.
    Shares of TriMas Corp traded up 3.74% during mid-day trading on Wednesday, hitting $29.95. TriMas Corp has a one year low of $18.26 and a one year high of $32.13. The stock’s 50-day moving average is currently $30.2. The company has a market cap of $1.177 billion and a P/E ratio of 17.40.
    TriMas Corp last released its earnings data on Tuesday, February 26th. The company reported $0.33 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.33. The company had revenue of $301.00 million for the quarter, compared to the consensus estimate of $291.23 million. During the same quarter in the previous year, the company posted $0.25 earnings per share. The company’s revenue for the quarter was up 15.9% on a year-over-year basis. TriMas Corp has set its FY13 guidance at $2.15-2.25 EPS. Analysts expect that TriMas Corp will post $2.21 EPS for the current fiscal year.
    Trimas Corporation (Trimas) is a manufacturer and distributor of products for commercial, industrial and consumer markets.

    Source: Zolmax

    Sentiment: Strong Buy

  • FDA Approves Novartis' Gleevec For Children With Acute Lymphoblastic Leukemia

    Sentiment: Strong Buy

94.38+0.20(+0.21%)Sep 16 4:04 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.